Screening for Prescription Drug Use Problems

Screeners are short questionnaires that employees can use on their own to recognize prescription drug use problems that could interfere with their health and safety at home and at work. This Issue Brief introduces the purpose of screeners and describes several tools that employers could easily place in existing wellness materials and messages.

Lyndsey works in a manufacturing plant. Her daughter, Cheryl, just started college and lives at home. Lyndsey has noticed that Cheryl is staying up late at night studying and recently seems jittery and irritable much of the time. This is unlike her usually laid-back daughter. Lyndsey is concerned.

Mike is an auto mechanic. He has had chronic back pain for several months following an incident at work where he “pinched his back” while lifting a tire. His work performance has not been up to par lately, and he often seems sleepy.

Cheryl and Mike are both misusing prescription drugs. Cheryl got a stimulant (amphetamine) from a classmate to help her concentrate and stay awake cramming for a test. She liked the drug so much that she began using it regularly and buys it from a guy she met at a party. Mike was given a prescription for OxyContin by his doctor. It helped a lot for a while, but he found himself craving more and more of the drug and, without his doctor’s knowledge, has gone to several other providers for prescriptions. Neither Cheryl nor Mike considers this misuse of prescription drugs to be a problem. Are they abusing these prescription drugs?

The Substance Abuse and Mental Health Services Administration (SAMHSA) defines nonmedical use of prescription drugs as the use of prescription pain relievers, tranquilizers, stimulants, or sedatives without a prescription for perceived medical need or for the experience or feeling the drug causes.¹ This definition covers a wide range of behaviors, from using someone else’s medication to address a legitimate medical need to misusing prescription medications to stay awake, get to sleep, calm down, or get high. Nonmedical prescription use, or misuse, is especially common among those with chronic pain, teenagers and young adults, and those with a history of addiction or other mental health problems, such as depression and anxiety.² A national survey conducted in 2012 shows that prescription drug misuse is a serious public health problem. Approximately 6.8 million Americans age 12 and above (2.6% of those surveyed) admitted to using prescription drugs nonmedically in the past month.¹ Many people at risk for misusing prescription drugs are working adults who may not understand the dangers of misusing drugs either not prescribed for them or not as prescribed by a health professional.

This Issue Brief was written to educate workers, employers, and community health center visitors about brief questionnaires (< 20 questions) called screeners. The screeners described here do not involve drug testing of bodily fluids. Instead, these screeners use questions or interviews to detect signs of prescription drug misuse or abuse in apparently healthy individuals so that health care can be provided early (before the problem becomes obvious).³ Screening for prescription drug misuse is performed for two reasons:

- to identify people at high risk for developing prescription drug abuse, and
- to determine whether an individual shows key indicators of prescription drug abuse.
Screening can help prevent misuse of prescription drugs, identify those at risk, discover a potential addiction problem, or point to a need for further evaluation and treatment. This is relevant for employers because early identification of prescription misuse symptoms may prevent prescription drug abuse and costly problems related to worker safety risks, reduced productivity, and medical treatment for substance abuse.

**Screening Instruments in the Workplace**

Traditionally, workplaces have relied on biological drug testing to detect drug users. Few question-based screeners have been developed specifically for use in the workplace, yet they could be very useful in helping employees, such as Lyndsey or Mike, to recognize the signs of prescription drug abuse by loved ones or to recognize and deal effectively with their own prescription drug misuse. Screeners for prescription drug abuse are needed to evaluate risk for the three classes of medications that are most often abused: opiate pain relievers (such as OxyContin and Vicodin), stimulants (such as Adderall and Vyvanse), and tranquilizers (agents that reduce anxiety, such as Valium and Xanax).

To address prescription drug abuse in the workplace, SAMHSA established the Preventing Prescription Abuse in the Workplace (PAW) program. This program provides technical assistance to workplaces across America to reduce prescription drug abuse. The SAMHSA PAW program is facilitating the development of a number of occupation-specific screeners for prescription drug abuse, such as the one developed for flight attendants to help them recognize potential abuse (see sidebar). Screeners geared to other workplace settings and occupations are in development.

While more studies are needed in this area, screeners such as the one developed for flight attendants may prove to be effective prevention tools for employees and their supervisors in the effort to reduce injuries and deaths.

---

**Example Screener: Flight Attendant Drug Use Screening Test**

Take the six-question drug use screening tool designed just for flight attendants. Routinely evaluate your drug use just as you would other health issues. Should you answer “yes” to two or more of the below questions, it means that your use may have moved into risky use. Please follow up with your flight attendant peer with the Flight Attendant Drug and Alcohol Program (FADAP). Your conversations are confidential.

1. I have not shown up for a trip because of my use of a drug or medication one or more times in the past 12 months.

2. I have used a flying partner’s prescription medication one or more times in the past 12 months.

3. I have shared my prescription medication with a flying partner one or more times in the past 12 months.

4. I have used a prescription pain medication while performing my flight duties one or more times in the past 12 months.

5. I have bid my flying schedule to avoid a drug test one or more times in the past 12 months.

6. I have bid my flying to have access to a drug or medication one or more times in the past 12 months.

**Available at**

[http://www.fadap.org/FlightAttendantDrugScreeningTool](http://www.fadap.org/FlightAttendantDrugScreeningTool)
Screeners Should Be Scientifically Sound

Screeners are developed based on their ability to identify correctly people with and without a condition. The two measures that determine a screener’s accuracy are sensitivity and specificity. The sensitivity of a test refers to the ability of the test to identify correctly those patients with a given condition (in this case, prescription drug abuse). For example, a test with 90% sensitivity correctly identifies 90% of those who are at risk for prescription drug abuse. The specificity of a screener refers to the ability of the screener to identify correctly those patients not at risk for prescription drug abuse. It is desirable to have a test that is both highly sensitive and highly specific. Screeners with a solid research base are recommended (see Table 1) because they have scientific evidence supporting their accuracy.

Currently Available Screeners

Screeners for substance abuse may be general—asking about tobacco, alcohol, illegal drug, and prescription drug use—or specific—meaning they target only one substance or class of drugs. General screeners for substance abuse detection typically are used for universal health screening (see Table 1). Most were developed to be administered by medical professionals but could be adopted for use by employees as self-administered, “take-home” flyers, or as part of wellness, health education, or workplace prescription drug abuse prevention programs. Tables 1 and 2 list the substances asked about in each screener, the populations they are intended to reach, websites where these screeners can be found, the number of questions asked in each screener, and studies supporting screeners’ use.

Currently, there are no brief specific screeners geared to detect stimulant or tranquilizer abuse. A 37-item questionnaire has been developed to identify risks for stimulant abuse among college students. Several brief screeners are being developed to detect prescription drug abuse risk among patients seeking opiate medications to control pain. Screeners are also available to monitor behaviors that may indicate medication abuse in patients being prescribed opiates (see Table 2).

This effort is in response to the widespread use of opiate medications that has led to high rates of overdose deaths in the United States. Opiates are especially dangerous when taken with other commonly used substances, such as alcohol and anti-anxiety agents. If providers are considering prescribing opiates, they can begin the process by using a screener to help guide them in developing a treatment plan. Screeners shown in Table 2 also could be adapted for use in workplaces or community health settings.

Response to a Positive Screen for Prescription Drug Abuse

No screener is 100% accurate. While science-based screeners are useful for predicting who is at risk for prescription drug abuse, they cannot be used to confirm a diagnosis. Screeners can miss people who have the condition, and people with a positive screen should be evaluated further. If someone screens positive, it is important that he or she seeks professional support. The first step is to schedule an appointment with a health care provider to talk about the problem or seek help from an Employee Assistance Program.

* Longer screeners were recommended in a recent review; these screeners included the Screener and Opioid Assessment for Patients with Pain–Revised, Addiction Behaviors Checklist, Prescription Drug Use Questionnaire, and the Patient Assessment and Documentation Tool.
<table>
<thead>
<tr>
<th>Instrument</th>
<th>Populations studied</th>
<th>Substances assessed</th>
<th>Instrument use and availability</th>
<th>Number of questions</th>
<th>Citations/rating*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)</td>
<td>Adults</td>
<td>Tobacco, alcoholic beverages, cannabis, cocaine, amphetamine-type stimulant, inhalants, hallucinogens, opioids, other</td>
<td>The document may be freely reviewed, abstracted, reproduced, and translated, in part or in whole, but it may not be sold or used in conjunction with commercial purposes. Available at <a href="http://www.who.int/substance_abuse/activities/assist/en/">http://www.who.int/substance_abuse/activities/assist/en/</a>. Copyright 2000, World Health Organization (WHO).</td>
<td>8</td>
<td>Strong support17-22</td>
</tr>
<tr>
<td>Drug Abuse Screening Test (DAST-10)</td>
<td>Adults, college students, pregnant women (an adolescent version is available)</td>
<td>Cannabis, inhalants, tranquilizers, barbiturates, cocaine, stimulants, hallucinogens, narcotics</td>
<td>This instrument may be used for noncommercial use (clinical, research, training purposes) as long as you credit the author, Dr. Harvey A. Skinner. Available at <a href="http://archives.drugabuse.gov/diagnosis-treatment/dast10.html">http://archives.drugabuse.gov/diagnosis-treatment/dast10.html</a>. Copyright 1982 by Harvey A. Skinner, PhD, and the Centre for Addiction and Mental Health, Toronto, Canada.</td>
<td>10</td>
<td>Strong support22-32-40</td>
</tr>
<tr>
<td>Drug Use Disorders Identification Test (DUDIT)</td>
<td>Adults</td>
<td>Cannabis, amphetamines, cocaine, opiates, hallucinogens, inhalants, GHB/other, sleeping pills/sedatives, painkillers</td>
<td>DUDIT is in the public domain, but the layout is copyrighted. This means that if one wants to use the DUDIT clinically or in research or to use the data presented in the DUDIT manual or the Berman et al. articles, then the DUDIT must be used as presented in the manual. The DUDIT is available at <a href="http://www.emcdda.europa.eu/attachements.cfm/att_10455_EN_DUDIT.pdf">http://www.emcdda.europa.eu/attachements.cfm/att_10455_EN_DUDIT.pdf</a>.</td>
<td>11</td>
<td>Strong support22-41-44</td>
</tr>
<tr>
<td>National Institute on Drug Abuse (NIDA)-Modified ASSIST (NM ASSIST)</td>
<td></td>
<td>Cannabis, cocaine, prescription stimulants, methamphetamine, inhalants, sedatives or sleeping pills, hallucinogens, stree opioids, prescription opioids, other</td>
<td>NM ASSIST was adapted from the WHO ASSIST, Version 3.0, and is available at <a href="http://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf">http://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf</a>.</td>
<td>8</td>
<td>Strong support17-22</td>
</tr>
<tr>
<td>NIDA Quick Screen</td>
<td></td>
<td>Alcohol, tobacco, prescription drugs for nonmedical use, illegal drugs</td>
<td>The NIDA Quick Screen was adapted from the single-question screen for drug use in primary care by Smith et al.46 and the National Institute on Alcohol Abuse and Alcoholism’s screening question on heavy drinking days. A paper version is available at <a href="http://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf">http://www.drugabuse.gov/sites/default/files/pdf/nmassist.pdf</a>. An electronic version can be found at <a href="http://www.drugabuse.gov/nmassist/?q=nida_questionnaire">http://www.drugabuse.gov/nmassist/?q=nida_questionnaire</a>.</td>
<td>1</td>
<td>Moderate/limited support45</td>
</tr>
<tr>
<td>RAFFT</td>
<td>Adolescents</td>
<td>Alcohol and other drugs</td>
<td>The assessment is available in the source reference.</td>
<td>5</td>
<td>Moderate/limited support46,47</td>
</tr>
</tbody>
</table>

*Rating scale: strong support—validated by three or more; moderate/limited support—validated by one or two independent trials.
### Table 2. Brief Screening Instruments Specific for Opiate Abuse Risk

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Populations studied</th>
<th>Prior to/during treatment</th>
<th>Instrument information and availability</th>
<th>Number of questions</th>
<th>Citations/rating*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid Risk Tool (ORT)(^{48})</td>
<td>Adults</td>
<td>Prior to treatment</td>
<td>Self-administered, office-based tool used to assist clinicians in assessing chronic pain patients’ risk for prescription opiate misuse. Available at <a href="http://www.painknowledge.org/physiciantools/ORT/ORT%20Patient%20Form.pdf">http://www.painknowledge.org/physiciantools/ORT/ORT%20Patient%20Form.pdf</a>.</td>
<td>5</td>
<td>Strong support(^{16;48-50})</td>
</tr>
<tr>
<td>Diagnosis, Intractability, Risk, Efficacy (DIRE)(^{51})</td>
<td>Adults</td>
<td>Prior to treatment</td>
<td>Clinician-administered tool used to assess which chronic, non-cancer pain patients will have effective analgesia and be compliant with long-term opioid maintenance treatment. Available at <a href="http://www.opioidrisk.com/node/1202">http://www.opioidrisk.com/node/1202</a>.</td>
<td>7</td>
<td>Moderate/limited support(^{49;51})</td>
</tr>
<tr>
<td>The Chabal 5-Point Opiate Abuse Checklist(^{55})</td>
<td>Adults</td>
<td>During treatment</td>
<td>Clinician-administered checklist that, within a clinic setting, relies on observable behaviors to identify chronic pain patients who are misusing their medication.</td>
<td>5</td>
<td>Moderate/limited support(^{55})</td>
</tr>
</tbody>
</table>

*Rating scale: strong support—validated by three or more; moderate/limited support—validated by one or two independent trials.*
For More Information

- Screening in Medical Settings:
  - National Coalition Against Prescription Drug Abuse: www.ncapda.org provides a list of the signs of prescription drug abuse.
  - National Institute on Drug Abuse quick screen:
    - http://www.drugabuse.gov/nmassist/?q=nida_questionnaire
  - Clinician’s Screening Tool for Drug Use in General Medical Settings:
    - http://www.drugabuse.gov/nmassist/
  - Substance Abuse and Mental Health Services Administration:
    - http://store.samhsa.gov/product/A-Guide-to-Substance-Abuse-Services-for-Primary-Care-Clinicians/SMA09-3740

- Screening Adolescents:
  - Substance Abuse and Mental Health Services Administration:
  - National Institute on Drug Abuse:

References

1) Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012. NSDUH Series H-44, HHS Publication No. SMA 12-4713.


50) Butler SF. Evidence of co-occurring alcohol and prescription opioid abuse in clinical populations: Implications for Screening, Presented at the Tufts Health Care Institute, Program on Opioid Risk Management Conference on Co-Ingestion of Alcohol with Prescription Opioids.


